Aktienanalyse zu Cabaletta Bio, Inc. (CABA)CABACabaletta Bio, Inc.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Cabaletta Bio Inc is currently not a strong buy due to its low current price of $1.47, which is significantly below the analyst price target of $30. The stock has a very low RSI of 29.175, indicating it is oversold. However, the company has raised $150 million through a share offering, which may provide necessary funding for its operations and growth. The main risk is the ongoing negative earnings trend, with a projected EPS of -0.34 for the upcoming quarter, which could further pressure the stock price.